Literature DB >> 216382

Pharmacokinetics and pharmacological effects of neostigmine in man.

T N Calvey, M Wareing, N E Williams, K Chan.   

Abstract

1 The pharmacokinetics of neostigmine was studied in six patients during the reversal of neuromuscular block induced by tubocurarine chloride. The effect of the drug on neuromuscular function was simultaneously assessed by electromyography. 2 Neostigmine was rapidly eliminated from plasma after intravenous administration. The decline in the plasma concentration of the drug was invariably resolved into two exponential components. The fast disposition (distribution) half-life of the drug was invariably less than 1 min; the slow disposition (elimination) half-life ranged from 15.4--31.7 min. 3 Neostigmine usually increased the amplitude of the compound muscle action potential and diminished electromyographic decrement within 2 min of intravenous injection. The pharmacological effect of neostigmine was usually maximal between 7 and 15 min. There was an inverse relationship between the plasma concentration of the drug and the facilitation of neuromuscular transmission. 4 Red cell acetylcholinesterase activity was almost completely inhibited within 2--3 min of intravenous injection of neostigmine. Enzyme activity recovered to approximately 28% of control values by 30 min and to 55% by 60 min.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 216382      PMCID: PMC1429427          DOI: 10.1111/j.1365-2125.1979.tb00915.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  HUMAN TISSUE CHOLINESTERASES: RATES OF RECOVERY AFTER INHIBITION BY NEOSTIGMINE; MICHAELIS-MENTEN CONSTANTS.

Authors:  R J KITZ
Journal:  Biochem Pharmacol       Date:  1964-09       Impact factor: 5.858

2.  Plasma clearance of neostigmine and pyridostigmine in rats with ligated renal pedicles.

Authors:  P A Burdfield; T N Calvey
Journal:  Eur J Pharmacol       Date:  1973-11       Impact factor: 4.432

3.  Inhibition of acetylcholinesterase in the brain and diaphragm of rats by a tertiary organophosphorous anticholinesterase and its quaternary analogue; in vivo and in vitro studies.

Authors:  R Lancaster
Journal:  J Neurochem       Date:  1972-11       Impact factor: 5.372

4.  Plasma concentration of edrophonium in man.

Authors:  T N Calvey; N E Williams; K T Muir; H E Barber
Journal:  Clin Pharmacol Ther       Date:  1976-06       Impact factor: 6.875

5.  Relationships between in vivo and in vitro inhibition of acetylcholinesterase (AChE) and impairment of neuromuscular transmission in the rat phrenic-nerve diaphragm by a tertiary anticholinesterase and its quaternary analogue.

Authors:  R Lancaster
Journal:  Biochem Pharmacol       Date:  1973-08-01       Impact factor: 5.858

6.  A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma.

Authors:  K Chan; N E Williams; J D Baty; T N Calvey
Journal:  J Chromatogr       Date:  1976-05-26

7.  Plasma clearance of neostigmine and pyridostigmine in the dog.

Authors:  P R Baker; T N Calvey; K Chan; C M Macnee; K Taylor
Journal:  Br J Pharmacol       Date:  1978-07       Impact factor: 8.739

  7 in total
  7 in total

Review 1.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 2.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

3.  Kinetics of intravenous pyridostigmine in man.

Authors:  T N Calvey; K Chan; A Dehghan; N E Williams
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

4.  Assessment of neuromuscular blockade by electromyography: a review.

Authors:  T N Calvey
Journal:  J R Soc Med       Date:  1984-01       Impact factor: 18.000

5.  Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy.

Authors:  Marie T Aouad; Waseem S Alfahel; Roland N Kaddoum; Sahar M Siddik-Sayyid
Journal:  BMC Anesthesiol       Date:  2017-04-11       Impact factor: 2.217

Review 6.  The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications.

Authors:  Jabril Eldufani; Gilbert Blaise
Journal:  Alzheimers Dement (N Y)       Date:  2019-06-04

7.  Novel Analgesic Index for Postoperative Pain Assessment Based on a Photoplethysmographic Spectrogram and Convolutional Neural Network: Observational Study.

Authors:  Byung-Moon Choi; Ji Yeon Yim; Hangsik Shin; Gyujeong Noh
Journal:  J Med Internet Res       Date:  2021-02-03       Impact factor: 5.428

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.